Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (DYN) announced that CEO Joshua Brumm and CSO Romesh Subramanian will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:00 a.m. ET. The presentation will focus on the company's dedication to developing innovative therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform.

A live webcast will be accessible on the company's Investors & Media website, with a replay available for 90 days post-presentation.

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

What is the date and time of Dyne Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

Dyne Therapeutics will present on January 13, 2021, at 10:00 a.m. ET.

Who will present for Dyne Therapeutics at the J.P. Morgan Healthcare Conference?

Joshua Brumm, the CEO, and Romesh Subramanian, the CSO, will present at the conference.

How can I listen to the Dyne Therapeutics' presentation at the conference?

A live webcast will be available on the Dyne Therapeutics Investors & Media section of their website.

What is the focus of Dyne Therapeutics' work?

Dyne Therapeutics focuses on developing therapeutics for genetically driven muscle diseases.

What is the FORCE™ platform used by Dyne Therapeutics?

The FORCE™ platform is a proprietary technology used to improve muscle tissue delivery of oligonucleotide therapeutic candidates.